prednisolone has been researched along with Hereditary Optic Neuroretinopathy in 2 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| " None of the nine patients had local or systemic adverse events related to the vector during the 9-month follow-up period." | 2.82 | Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy. ( Chen, C; Dong, XY; He, H; Hu, WK; Li, B; Ma, SQ; Pei, H; Wan, X; Wang, DW; Yang, S; Zhang, G; Zhao, MJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heidari, E | 1 |
| Rasoulinezhad, M | 1 |
| Pak, N | 1 |
| Reza Ashrafi, M | 1 |
| Heidari, M | 1 |
| Banwell, B | 1 |
| Garshasbi, M | 1 |
| Reza Tavasoli, A | 1 |
| Wan, X | 1 |
| Pei, H | 1 |
| Zhao, MJ | 1 |
| Yang, S | 1 |
| Hu, WK | 1 |
| He, H | 1 |
| Ma, SQ | 1 |
| Zhang, G | 1 |
| Dong, XY | 1 |
| Chen, C | 1 |
| Wang, DW | 1 |
| Li, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy[NCT03153293] | Phase 2/Phase 3 | 159 participants (Actual) | Interventional | 2017-12-27 | Active, not recruiting | ||
| Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy[NCT01267422] | 9 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months[NCT03428178] | 120 participants (Actual) | Interventional | 2018-01-08 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01267422)
Timeframe: Up to 3 years
| Intervention | mmHg (Mean) |
|---|---|
| IOP Before Treatment | 14 |
| IOP After Treatment | 16 |
The mean of Neutralizing antibody assay of 8 patients before and after treatment (NCT01267422)
Timeframe: up to 3 years
| Intervention | titer (Mean) |
|---|---|
| The Mean of Neutralizing Antibody Assay Before Treatment | 0.9221 |
| The Mean of Neutralizing Antibody Assay After Treatment | 0.8723 |
Average RNFL thickness of 8 patients througth Optical coherence tomography(OCT) test before and after treatment (NCT01267422)
Timeframe: Up to 3 years
| Intervention | Micrometer (Mean) | |
|---|---|---|
| injected eye | uninjected eye | |
| Average RNFL Thickness After Treatment | 46.7813 | 47.9688 |
| Average RNFL Thickness Before Treatment | 47.3125 | 50.1875 |
MD: mean deviation, the value Close to 0 regarded normal.VFI/MD：The bigger one was more close to the normal value. (NCT01267422)
Timeframe: up to 3 years
| Intervention | dB (Mean) | |
|---|---|---|
| injected eye | uninjected eye | |
| Mean MD After Treatment | -23.813 | -23.427 |
| Mean MD Before Treatment | -29.377 | -28.701 |
VFI: visual field index ,the value Close to 100% regarded normal. VFI/MD：The bigger one was more close to the normal value. (NCT01267422)
Timeframe: up to 3 years
| Intervention | Percentage of normal (Mean) | |
|---|---|---|
| injected eye | uninjected eye | |
| Mean VFI After Treatment | 28 | 25 |
| Mean VFI Before Treatment | 11 | 10.5 |
The mean percentage of CD3+/CD4+/CD8+ test before and after treatment (NCT01267422)
Timeframe: up to 6 months
| Intervention | Percentage of total cells (Mean) | ||
|---|---|---|---|
| Values of CD3+ | Values of CD4+ | Values of CD8+ | |
| The Mean Percentage of CD3+/CD4+/CD8+ After Treatment | 53 | 20 | 13 |
| The Mean Percentage of CD3+/CD4+/CD8+ Before Treatment | 51 | 26 | 20 |
(NCT01267422)
Timeframe: Up to 3 years
| Intervention | logMAR (Mean) | ||||
|---|---|---|---|---|---|
| before treament | 1 months after treament | 3 months after treament | 6 months after treament | 9 months after treament | |
| BCVA of Treated Eyes | 1.69 | 1.58 | 1.38 | 1.23 | 1.27 |
| BCVA of Un-treated Eyes | 1.40 | 1.36 | 1.31 | 1.20 | 1.23 |
1 trial available for prednisolone and Hereditary Optic Neuroretinopathy
| Article | Year |
|---|---|
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.
Topics: Administration, Oral; Adolescent; Adult; Child; Dependovirus; Electroretinography; Female; Follow-Up | 2016 |
1 other study available for prednisolone and Hereditary Optic Neuroretinopathy
| Article | Year |
|---|---|
Defective complex III mitochondrial respiratory chain due to a novel variant in CYC1 gene masquerades acute demyelinating syndrome or Leber hereditary optic neuropathy.
Topics: Amino Acid Substitution; Base Sequence; Brain; Child; Computer Simulation; Electron Transport; Elect | 2021 |